2012 saw plenty of M&A activity, expansion into emerging markets but also job cuts as companies streamline their operations and cut costs. There was also investment in new plants to meet growth in demand. Jane Ellis reports
There were several significant deals during 2012, none bigger than Watson Pharmaceutical’s purchase of the Actavis Group for US$5.4bn, which created the world’s third-largest generics company, with combined sales expected to be in excess of $8bn. The new company will be called Actavis from the beginning of next year and will employ 17,000 people. Headquartered in New Jersey, US, Watson is also to start a multi-year rebranding campaign for its facilities, operations and commercial presence in 2013.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.Featured companies
Lonza
At Lonza, we enable a healthier world by supporting our healthcare customers on the path to commercialization. Our community of around 17,500 skilled employees work across a...
PCI Pharma Services
PCI Pharma Services: Your bridge between life-changing therapies and patients.
Gerresheimer
Gerresheimer is the global partner for pharmaceutics, biotech, healthcare, and cosmetics with a very broad product range for pharmaceutical and cosmetic containment solutions...
Piramal Pharma Solutions
Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO), offering end-to-end development and manufacturing solutions across the drug life...
- Companies:
- BASF Personal Care and Nutrition GmbH
- GlaxoSmithKline
- Merck MSD
- Patheon
- Dr Reddys Laboratories
- Orchid Chemicals and Pharmaceuticals Ltd
- SCM Pharma
- Bosch
- Pfizer
- Sanofi
- Hospira
- AstraZeneca
- Aptar Beauty
- Axplora
- Takeda
- Redx Pharma
- Amgen
- Actavis
- Merck Electronics KGaA
- Aenova Group
- Novartis
- IQVIA